Introduction
Prostate cancer (PC) is the most common malignancy in males and the second leading cause of cancer-related death in the United States and Europe (Gronberg, 2003) . The incidence of PC has been significantly increasing in most developed countries because of the prevalence of a Western-style diet and explosion of the aging population (Hsing and Devesa, 2001; Gronberg, 2003) . The screening using serum prostate-specific antigen led to the dramatic improvement of early detection of PC and resulted in an increase in the proportion of patients with a localized disease that could be curable by surgical and/or radiation therapies (Hsing and Devesa, 2001; Gronberg, 2003) . However, 20-30% of these PC patients still suffer from a relapse of the disease (Feldman and Feldman, 2001; Scher and Sawyers, 2006) . Androgen/androgen receptor (AR) signaling pathway have a central role in PC development and progression, and PC growth is usually androgen-dependent (Feldman and Feldman, 2001; Scher and Sawyers, 2006) . Hence, most of the patients with relapsed or advanced disease respond well to androgen-ablation therapy, which suppresses testicular androgen production by surgical or medical castration. Nonetheless, they eventually acquire tolerance to androgen-ablation therapy and more aggressive phenotype that are termed castration-resistant prostate cancers (CRPCs), which are basically lethal (Feldman and Feldman, 2001; Grossmann et al., 2001; Scher and Sawyers, 2006) .
The mechanism of this castration-resistant progression could be divided into two pathways, one still involving AR and the other independent of AR, and these two mechanisms are not mutually exclusive of each other and often coexist in CRPC cells (Feldman and Feldman, 2001; Scher and Sawyers, 2006) . The CRPC phenotype where PC cells can survive under castration is mainly dependent on AR reactivation (Scher and Sawyers, 2006) . The activation of multiple AR-independent cell-growth pathways in CRPC cells can contribute to their more malignant or aggressive phenotype. Among them, the PTEN-phosphatidylinositol 3-kinase (PI3K)-Akt pathway is likely to be one of the most critical pathways that can explain the malignant or aggressive phenotype of CRPCs. Akt is a serine/ threonine kinase that is activated through the phosphatidylinositol (3,4,5)-phosphate (PIP3)-PI3K pathway, and activated or phosphorylated Akt can contribute to cell growth, proliferation, protection from proapoptotic stimuli and stimulation of neo-angiogenesis by regulating GSK3-b (Pap and Cooper, 1998) , BAD (Datta et al., 1997) , FOXO (Burgering and Kops, 2002) and mTOR (Hay, 2005) . In normal cells, the tumor suppressor PTEN, a lipid phosphatase that removes phosphate from PIP3, inhibits Akt activation and allows cells to undergo apoptosis (Orloff and Eng, 2008) . On the other hand, tumor cells harboring PTEN mutation or loss of PTEN expression cause Akt activation. This Akt pathway is considered a key determinant of biological aggressiveness of various cancers and a major potential target for novel anti-cancer therapies (Vivanco and Sawyers, 2002; Mitsiades et al., 2004 ). In fact, the level of phosphorylated Akt was elevated in high Gleason grade PC and was associated with PC progression (Malik et al., 2002; Kreisberg et al., 2004) . Akt requires its phosphorylation at the Thr308 and Ser473 residues for its activation, and the phosphorylation of Thr308 is known to be catalysed by phosphoinositidedependent kinase 1. A number of kinases have been suggested to function as the so-called PDK2, which catalyses the phosphorylation of Ser473, but it is still unclear which of them functions biologically as PDK2 in cancer cells (Scheid and Woodgett, 2001) .
The cAMP-dependent protein kinase A (PKA) is often considered to be essential for mediating the wide range of physiological or pathological effects initiated by cAMP. Coupling with G-proteins, it activates a number of ligand-receptor signaling pathways and controls cell growth and differentiation (Stork and Schmitt, 2002; Tasken and Aandahl, 2004) . In PC, several reports have suggested its involvement with androgen-independent growth and neuroendocrine differentiation (Cox et al., 2000; Deeble et al., 2007) , as well as with the cross-talk between the PKA and AR pathways in PCs (Sadar, 1999; Stork and Schmitt, 2002) . The PKA pathway is regulated by many factors, including PKA-regulatory subunits (PKA-Rs) and endogenous PKA inhibitors (Miller, 2002; Taylor et al., 2005) . There are three PKA inhibitor (PKI) members reported so far (a, b and g), of which PKIA (PKI-a) is a totally specific inhibitor of PKA and its binding and inhibitory effects to PKA have been extensively characterized (Wiley et al., 1999; Dalton and Dewey, 2006) . On the other hand, the inhibitory effect of protein kinase inhibitor-b (PKIB), which shares only a 40% amino acid identity with PKIA, was much smaller than that of PKIA (Dalton and Dewey, 2006) and was not fully characterized. In cancer cells, these regulatory factors were shown to be aberrantly expressed and to modify the PKA pathway, and some of them are considered to be targets for cancer treatment (Miller, 2002) .
Previously, we characterized the molecular feature of clinical CRPCs through the genome-wide cDNA microarray analysis of cancer cells purified from CRPC tissues, and identified a number of up-regulated genes, some of which might be involved in their castrationresistant and aggressive phenotype (Tamura et al., 2007) . Further, applying such information in this study, we report a novel molecular target, PKIB (PKI-b), which is presumed to be one of the regulatory factors in the PKA pathway that can contribute to PC cell viability and its aggressive phenotype through functional linking between the PKA and Akt pathways.
Results
Overexpression of PKIB in PC Among dozens of overexpressed genes that were identified by our genome-wide cDNA microarray analysis of CRPC cells (Tamura et al., 2007) , we focused on PKIB in this study. Semi-quantitative reverse transcriptase (RT)-PCR confirmed PKIB overexpression in all of the five CRPC cells that were microdissected from CRPC tissues, compared with that in normal prostatic epithelial cells (NP mix), which were also microdissected from five normal prostate tissues. The expression of PKIB was much higher in CRPC than in castration-naı¨ve PC (CNPC) cells and normal vital organs including the lung, heart, liver and kidney ( Figure 1a ). Northern blot analysis using a cDNA fragment of PKIB as a probe identified an about 1.3-kb transcript only in the placenta, but no expression was detected in any vital organs ( Figure 1b) . Next we generated a polyclonal antibody to human PKIB and validated PKIB protein expression in clinical PC tissues. Western blot analysis specifically detected the endogenous PKIB in the clinical PC tissues and the placenta tissue as a positive control (Supplementary materials). Immunohistochemical analysis by using an anti-PKIB antibody on 59 clinical PC tissues, including 50 CNPCs and nine CRPCs, indicated no or weak staining (þ) of PKIB in precursor lesion prostatic intraepithelial neoplasias (PINs) and normal prostate epithelium (Figure 1c ). Although 28 (56%) of 50 CNPCs showed no or weak expression (þ) of PKIB, the remaining 22 CNPCs and all of nine CRPCs revealed strong positivity ( þ þ ) of PKIB in concordance with the results of RT-PCR analysis. Interestingly, nine of ten CNPCs with a Gleason score of 8 or higher showed strong positivity (þ þ) of PKIB, whereas none of 10 CNPCs with a Gleason score of 6 or lower showed strong positivity (þ þ), as summarized in Figure 1d . Gleason scores in clinical CNPC tissues were significantly correlated with PKIB expression levels (w 2 -test, Po0.001), indicating that PKIB might be involved in aggressive phenotype and poor prognosis of PCs.
Knockdown effect of PKIB on PC cell growth and invasion To investigate the biological roles of PKIB overexpression in PC cells, we constructed several short-hairpin RNA (shRNA) expression vectors (si1, si2, si3 and siCON) to knock down the PKIB expression. Two PC cell lines, 22Rv1 and LNCaP cells, were transfected with each of them and confirmed the significant knockdown effect of si1 and si2 by semi-quantitative RT-PCR, whereas no effect on PKIB expression was observed by si3 and a negative-control siCON (Figure 2a ). MTT assay ( Figure 2b ) and colony formation assay ( Figure 2c ) using 22Rv1 cells and LNCaP cells showed that the introduction of si1 and si2 shRNA vectors drastically attenuated their cell growth or viability. On the other hand, other shRNAs, which revealed no knockdown effect on PKIB expression, did not suppress PC cell growth, indicating that PKIB was likely to have some important functions in PC cell viability. Next, to investigate the influence of PKIB on cell cycle or apoptosis, we analysed the cell cycle phase in PKIB knockdown by flow cytometry. As shown in Figure 2d , knockdown of PKIB expression in PC cells by oligo duplex siRNA (siPKIB) resulted in a significant increase in the G0/G1 population (73%, right) compared with the control siEGFP (55%, left), implicating the induction of G0/G1 cell cycle arrest by PKIB knockdown. Furthermore, to examine a possible function of PKIB in cellular invasion, we knocked down PKIB in PC cell line PC-3 and carried out Matrigel invasion assay. As shown in Figure 2e , knockdown of PKIB (siPKIB) drastically decreased the invasion ability of PC cells as well as their growth.
Overexpression of PKIB promoted PC cell growth and invasion To further investigate the oncogenic function of PKIB, we generated three DU145-derived clones that constitutively expressed exogenous PKIB (Figure 3a) PKIB overexpression in prostate cancer S Chung et al three DU-145-derived clones (#1, #2 and #3) expressing exogenous PKIB grew more rapidly than did mock cells (Figure 3b ), suggesting the growth-promoting effect of PKIB on PC cells. BrdU incorporation assay also indicated higher proliferation in PKIB-expressing DU-145 cells (#1, #2, and #3) than in mock cells (Figure 3c ). Regarding cellular invasion, NIH3T3 cells transfected with PKIB-expressing vector significantly enhanced their migration or invasion ability through Matrigel, compared with the cells transfected with mock vector (Figure 3d ), implicating the involvement of PKIB with invasion ability.
PKIB interacted with protein kinase A catalytic subunit (PKA-C) and involved nuclear translocation of PKA-C Protein kinase inhibitor-b belongs to the PKI (protein kinase A inhibitor) family, whereas PKA inhibitor-a (PKIA) could inhibit the kinase activity of the PKA-C and export PKA-C from the nucleus to the cytoplasm by binding to PKA-C directly through its pseudosubstrate motif (Wiley et al., 1999; Wen et al., 1994) . PKIB also has this motif, but its inhibitory activity was much smaller than that of PKIA (Gamm and Uhler, 1995; Dalton and Dewey, 2006) and the involvement of PKIB in the intracellular translocation of PKA-C is unknown. To investigate for a possible interaction between PKIB and PKA-C, we co-transfected HA-PKIB and PKA-CMyc expression vectors into COS-7 cells, and their cell lysates were immunoprecipitated by HA-tag antibody. As shown in Figure 4a , PKA-C-Myc was co-immunoprecipitated with HA-PKIB, indicating the interaction between PKIB and PKA-C. We also confirmed the direct interaction between glutathione S-transferase (GST)-fused recombinant PKIB and exogenous PKA-C in vitro (Figure 4b ). Subsequently, we knocked down PKIB in PC-3 cells and examined the subcellular localization of endogenous PKA-C. Immunocytochemical analysis revealed the presence of PKA-C protein in the nucleus in PC-3 cells transfected with the control siRNA or those without any transfection, although the majority of PKA-C protein was localized in the cytoplasm (Figure 4c, left) . However, when PKIB expression was knocked down in PC-3 cells by siPKIB, no or very little signal of the PKA-C was observed in the nucleus (Figure 4c, right) . A similar pattern of the PKA-C localization was observed when we used another PKIB-expressing PC cell line LNCaP (data not shown).
To further analyse the nuclear localization of PKA-C more quantitatively, we fractionated the lysates from LNCaP cells as shown in Figure 4d and found that the amount of PKA-C in the nucleus was slightly decreased in PKIB knockdown, compared with that in the control siRNA. These findings implicate that PKIB could facilitate the import of PKA-C to the nucleus or inhibit the export of PKA-C from the nucleus, unlike the nuclear exporting function of the other family member PKIA.
PKIB was involved with Akt phosphorylation in PC cell
There are several lines of evidence suggesting that the PTEN-PI3K-Akt pathway can have critical functions in PC progression and CRPC emergence. Hence, we focused on the PTEN-PI3K-Akt pathway and investigated whether PKIB and/or PKA-C could affect Akt phosphorylation in PC cells or not. First, we knocked down PKIB expression in two PC cell lines, LNCaP and PC-3, by siRNA and examined the phosphorylation level of Akt at Ser473 by western blot analysis. As shown in Figure 5a , PKIB knockdown clearly affected the Akt phosphorylation in these PC cells. Concordantly, we observed that the additional expression of PKIB in PC cells significantly enhanced the Akt phosphorylation at Ser473 (Figure 5b ). Speculating that PKIB could directly interact with PKA-C kinase and possibly modify its kinase function, we enforced PKA-C expression in PC cells and observed that overexpression of PKA-C kinase also enhanced Akt phosphorylation at Ser473 (Figure 5c ). These findings implied that PKIB could be involved in Akt phosphorylation (Ser473) in PC cells, possibly through the modification of PKA-C kinase function. To further investigate whether PKA-C alone or together with PKIB could phosphorylate Ser473 of Akt directly, we carried out an in vitro kinase assay using recombinant PKIB, PKA-C kinase and Akt proteins. As shown in Figure 5d , western blot analysis using the phosphorylated Ser473-specific antibody revealed that the phosphorylation level of Akt (Ser473) was significantly enhanced by the addition of PKIB in the in vitro reaction, suggesting that PKIB could enhance PKA-C kinase activity for Akt-Ser473.
Akt phosphorylation and PKIB overexpression in PC tissues Finally, we examined the correlation between PKIB expression and Akt phosphorylation at Ser473 in clinical PC tissues. Pictures representing a comparison of the staining patterns of PKIB ( Figure 6a ) and phosphorylated Akt at Ser473 (Figure 6b ) in the face-on-face slides of PC tissues indicated the correlation between PKIB 
Discussion
This study identified a novel candidate target molecule, PKIB, for the development of treatment for PCs, especially for aggressive PCs and CRPCs. PC shows relatively good prognosis, and hormone-ablation therapy or castration is effective in most of the relapsed or advanced PC. However, once CRPC cells emerge, there are very limited options for PC patient care, such as doxotaxel plus predonisone (Petrylak et al., 2004; Tannock et al., 2004) , which can still offer the limited effect on CRPCs. Hence, it is most essential to identify molecular targets for CRPCs and develop novel therapies to target those molecules. As shown in this study, owing to its restrictive expression in adult normal organs and its critical functions in PC cells, PKIB and its association with PKA-C kinase could be promising targets for a novel therapeutic approach with a minimal risk of adverse effects.
Functionally, PKIB is likely to be associated with PKA-C in two aspects at least. One is the change of PKA-C localization into the nucleus, and another is the modification of the PKA-C kinase activity. These functions are independent and PKIB could function both in the nucleus and the cytoplasm. PKA-C kinase also functions both in the nucleus and the cytoplasm and has multiple substrates in the nucleus and the cytoplasm. The translocation of PKA-C to the nucleus through PKIB is not related to Akt phosphorylation but to other unknown target molecules in the nucleus of PC cells.
There is a growing body of evidence supporting that Akt activation or phosphorylation could have critical functions in malignant phenotypes of PC, including a castration-resistant phenotype (Kreisberg et al., 2004; Scher and Sawyers, 2006) . Hence, our result implying that PKIB enhanced the kinase activity of PKA-C for Akt phosphorylation at Ser473 is very important. Our in vivo experiments and in vitro kinase assay showed that PKA-C could have some potential to phosphorylate Akt-Ser473, as reported previously (Filippa et al., 1999) , and that PKIB could facilitate this kinase activity for Akt-Ser473 as a PDK2. At least 10 kinases have been suggested to function as putative PDK2s, including mitogen-activated protein kinase (MAPK), integrinlinked kinase, protein kinase C-a and mTOR, and recent biochemical studies have strongly suggested that TORC2 (mTOR-Rictor complex) is the elusive PDK2 for Akt-Ser473 (Sarbassov et al., 2005; McDonald et al., 2008) . In addition to them, our study showed clear Glutathione S-transferase (GST)-pull down assay was carried out using the GST-fused PKIB. The cell lysate of PKA-C transfected COS-7 cells were incubated with GST-PKIB or GST as a negative control. GST and GST-PKIB were detected by an anti-GST antibody and PKA-C was detected by an anti-PKA-C antibody. PKA-C was pulled down by GST-PKIB, but not by GST. (c) Immunocytochemical analysis observed that most of the PKA-C was localized in the cytoplasm and some signals of PKA-C protein in the nucleus (left) when PC-3 cells were transfected with a negative-control siRNA duplex (siEGFP). On the other hand, when siRNA duplex knocked down endogenous PKIB in PC-3 cells (siPKIB), immunocytochemical analysis showed no or very little signal of PKA-C in the nucleus (right). (d) In knockdown of PKIB in LNCaP cells, the cells were fractionated to the nuclear and the cytoplasmic fractions to analyse the nuclear PKA-C more quantitatively. Thirty mg proteins of the fractionated cell lysates were western-blotted by using anti-PKA-C antibody, anti-laminB antibody and anti-HSP90 antibody for the nucleus and the cytoplasmfractionated controls, respectively. The amount of PKA-C in the nucleus was slightly decreased in PKIB knockdown by siPKIB, compared with that in a negative-control siEGFP. IP, immunoprecipitation; IB, immunoblot. PKIB overexpression in prostate cancer S Chung et al evidence supporting that PKA-C could phosphorylate Akt-Ser473 by incorporating with PKIB, at least in PC cells, and, most importantly, that it could contribute to more aggressive and malignant phenotype of PCs.
A substantial minority (B15%) of human PCs harbors PTEN mutations, and PI3K mutation or amplification is also very rare in PCs and CRPCs (Feilotter et al., 1998; Majumder and Sellers, 2005) . Although we cannot exclude other genetic or epigenetic losses of PTEN, other mechanisms may contribute to the activation of the PTEN-PI3K-Akt pathway in PCs (Majumder and Sellers, 2005) . PKIB overexpression and its enhancing effect on PKA-C kinase activity as a PDK2 may be able to explain Akt activation in some proportion of PCs and CRPCs, although the precise mechanism about how PKIB could facilitate phosphorylation of Akt (Ser473) by PKA-C kinase is still not clarified. When PKA-C kinase binds to PKIB and other factors, its conformation might be changed to have an affinity to the Akt protein as a substrate. We also investigated intensively the phosphorylation status of other established or possible substrates for PKA-C kinase, including cAMP-response element (CRE) binding protein, NF-kB, p38 MAPK and ERK (Lalli and Sassone-Corsi, 1994; Shaywitz and Greenberg, 1999; Chio et al., 2004) , by knockdown and overexpression of PKIB in PC cells, but we did not observe any significant or consistent effect on the phosphorylation status of these other substrates. Hence, Akt is a kinase substrate preferable for PKA-C kinase incorporating with PKIB in PC cells.
There are still several questions about the expression and function of PKIB. What mechanism causes PKIB to be overexpressed in CRPCs and aggressive PCs? There is no report about the amplification or demethylation of PKIB gene or locus in PC. How could PKIB modify the kinase activity of PKA-C? The structural analysis of the interaction between PKA-C and PKIA, which might help to solve this question, has already been reported (Knighton et al., 1991) , and these issues should be clarified by further investigation.
In conclusion, we here identified PKIB as a novel molecular target for PCs, especially for aggressive PCs and CRPCs, and through the modification or enhancement of PKA-C kinase, PKIB could strongly associate with Akt-Ser473 phosphorylation, which could have critical functions in aggressive and malignant phenotype of PCs, including CRPCs.
Materials and methods
Cell lines COS-7 cells and NIH3T3 cells as well as PC cell lines LNCaP, 22Rv1, PC-3 and DU-145 were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). They were grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA); the media were supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic/ antimycotic solution (Sigma-Aldrich, St Louis, MO, USA).
Cells were maintained at 37 1C in atmospheres of humidified air with 5% CO 2 .
Semi-quantitative RT-PCR
Purification of PC cells and normal prostatic epithelial cells from frozen clinical PC tissues has been described previously (Tamura et al., 2007) . RNAs from these samples were subjected to two rounds of T7-based RNA amplification (Epicentre Technologies, Madison, WI, USA) and subsequent synthesis of single-strand cDNA. Total RNAs from PC cell lines were extracted using the RNeasy Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's recommendation. Extracted RNAs were treated with RNase-Free DNase Set (Qiagen) and reverse transcribed to single-stranded cDNAs using d(T) 12À18 primer with Superscript II reverse transcriptase (Invitrogen). The primer sequences we used were forward 5 0 -TTGGCTTGACTCAGGATTTA-3 0 and reverse 5 0 -ATGC TATCACCTCCCCTGTG-3 0 for b-actin (ACTB), forward 5 0 -GGCACATACTAGAAGCAAAATACG-3 0 and reverse 5 0 -GATGGGCAAATCATTCTTGGTA-3 0 for PKIB (GeneBank Accession no: NM_181795). The RT-PCR exponential phase was determined to allow semi-quantitative comparisons among cDNAs developed from identical reactions. Each PCR regime involved a 98 1C, 30 s initial denaturation step followed by 22 cycles (for ACTB), 23 cycles (for PKIB), and at 98 1C for 10 s, 55 1C for 5 s, and 72 1C for 30 s on a Gene Amp PCR system 9600 (PE Applied Biosystems, Foster City, CA, USA).
Northern blot analysis
The 261-bp probe specific to PKIB was prepared by PCR using the primer set described above. Hybridization on MTN (Multiple Tissue Northern) blot (Clontech, Mountain View, CA, USA) with a random-primed, a 32 P-dCTP-labeled probe was carried out according to the instructions for Megaprime DNA labeling system (GE Healthcare, Amersham Place, Bucks, UK). Prehybridization, hybridization and washing were performed according to the supplier's recommendations. The blots were autoradiographed with intensifying screens at À80 1C for 7 days.
Antibody generation and immunohistochemistry
The two KLH-conjugated peptides from human PKIB (SARAGRRNALPDIQSSAATD and KEKDEKTTQDQ-LEKPQNEEK) were synthesized and immunized into rabbits, and the immune sera were purified on affinity columns packed with Affi-Gel 10 activated affinity media (Bio-Rad Laboratories, Hercules, CA, USA), conjugating each of the peptide antigens in accordance with basic methodology. Conventional sections from PC tissues were obtained from surgical specimens, and CRPC tissues were obtained by autopsy and transurethral resection of the prostate as described previously (Tamura et al., 2007) . The sections were deparaffinized and autoclaved at 108 1C in Dako Cytomation Target Retrieval Solution High pH (Dako, Carpinteria, CA, USA) for 15 min. After blocking of endogenous peroxidase and proteins, the sections were incubated with anti-PKIB antibody (diluted by 1:80) or anti-phospho-Akt 1(Ser473, Cell Signaling Technology, Beverly, MA, USA, diluted by 1:50) at room temperature for 60 min. After washing with phosphate-buffered saline (PBS), immunodetection was performed with peroxidase-labeled antirabbit immunoglobulin (Envision kit, Dako). Finally, the reactants were developed with 3,3 0 -diaminobenzidine (Dako). Counterstaining was carried out using hematoxylin.
ShRNA-expressing constructs and transfection
To knock down endogenous PKIB expression in PC cells, we used psiU6BX3.0 vector for expression of shRNA against a target gene as described previously (Tamura et al., 2007) . The target sequences of shRNA for PKIB were as follows: si1; 5 0 -GCCCTAAGCAGCATGTGTA-3 0 , si2; 5 0 -GCAGTAGGC ACTTAAGCAT-3 0 , si3; 5 0 -GATGCAAAAGAGAAAGATG-3 0 and a control shRNA; 5 0 -GCGCGCTTTGTAGGATTCG-3 0 (siCON; 5 and 16 s rRNAs of Euglena gracilis). PC cell lines 22Rv1 and LNCaP were plated onto 10-cm dishes or six-well plates, and transfected with plasmid designed to express shRNA to PKIB (8 mg/dish, 3 mg/well) using FuGENE6 (Roche, Basel, Switzerland) according to the manufacturer's instructions. Cells were selected by 0.8 mg/ml of Geneticin (Sigma-Aldrich) for 7 days and then harvested to analyse the knockdown effect on PKIB expression. RT-PCR for PKIB was carried out by using primers, forward 5 0 -ATGAGGACA GATTCATCAAAAAT-3 0 and reverse 5 0 -CACTTTGGTTTT ATTTTTGCTCC-3 0 . For colony formation assay, transfectants expressing shRNAs were grown for 20 days in media containing Geneticin. After fixation with 100% methanol, the transfected cells were stained with 0.1% of crystal violet-H 2 0 to assess colony formation. Cell viability was quantified using Cell counting kit-8 (DOJINDO, Kumamoto, Japan). After 20-day culturing in the Geneticin-containing medium, the solution was added at a final concentration of 10%. Following incubation at 37 1C for 2 h, absorbance was measured at 490 nm, and at 630 nm as a reference, with a Microplate Reader 550 (Bio-Rad).
DNA cell cycle analysis
We synthesized the RNA duplex corresponding to the sequence si1 (siPKIB; 5 0 -TTGCCCUAAGCAGCAUGU AUA-3 0 and 5 0 -TTUACACAUGCUGCUUAGGGC-3 0 ) to knock down endogenous PKIB more efficiently. LNCaP cells were plated onto 10-cm dishes and transfected with siRNA duplex specific to PKIB (siPKIB) or siRNA duplex specific to EGFP (siEGFP; 5 0 -TTGAAGCAGCACGACUUCUUC-3 0 and 5 0 -TTGAAGAAGUCGUGCUGCUUC-3 0 ) as a control (450 pmol of each) by using Lipofectamin 2000 (Invitrogen) according to the manufacturer's recommended procedures. After 48 h, cells were harvested and washed with cold PBS(À). The pellet was resuspended and fixed overnight with 70% ethanol in 1 Â PBS(À) at 4 1C. The cells were centrifuged and resuspended in 250 ml PBS(À) containing RNase A (final concentration 1 mg/ml), and incubated for 30 min at 37 1C. After incubation, 250 ml of propidium iodide (50 mg/ml final concentration) was added to the cells. The DNA content was measured by flow cytometry (Cell Lab Quanta SC MPL, Beckman Coulter Inc., Fullerton, CA, USA).
Generation of PKIB-overexpressing cells and growth assay
The cDNA encoding an open reading frame of PKIB was amplified by PCR, and the PCR-amplified product was cloned into pIRES vector (Clontech). The plasmids were transfected into the DU145 using FuGENE6 (Roche) according to the manufacturer's recommended procedures. A population of cells was selected with 0.6 mg/ml Geneticin, and clonal DU145 cells were sub-cloned by limiting dilution. PKIB expression was confirmed by western blot analysis using an anti-HA antibody (Roche), and three clones that expressed PKIB constitutively were established. Control DU145 cells transfected with empty pIRES/HA vector were also established as mock cells. For in vitro growth assay, 2 Â 10 3 cells of three PKIB stable clones (#1, #2 and #3) or the control clone (Mock mix) were seeded into each well of a 48-well culture plate and incubated in DMEM containing 5% FBS. The growth curve of these established clones was measured by using the Cellcounting kit-8 (DOJINDO). For the BrdU cell proliferation assay, PKIB stably expressed DU145 cells were seeded 1 Â 10 3 cells per well into a 96-well plate. Cells were cultured for 5 days in DMEM with 10% FBS and 0.8 mg/ml Geneticin. BrdU in DMEM (final concentration 10 mM) was added and incubated for 4 h, and a colorimetric BrdU incorporation assay was carried out using a Cell proliferation enzyme-linked immunosorbent assay, BrdU colorimetric kit (Roche) according to the manufacturer's recommended procedures.
Matrigel invasion assay NIH3T3 cells transfected either with plasmids expressing PKIB (pcDNA3.1/HA-PKIB) or with mock plasmids were grown to near confluence in DMEM containing 10% FBS. To knock down PKIB, PC-3 cells were transfected with oligo siPKIB or control oligo siEGFP (as described above) and incubated for 48 h in DMEM containing 10% FBS. After incubation, the cells were harvested by trypsinization, washed in DMEM without addition of serum or proteinase inhibitor, and suspended in DMEM. 3.75 Â 10 5 of the cells in 0.75 ml DMEM containing 10% FBS were seeded in a Matrigel matrix chamber (BD Biosciences, Franklin Lakes, NJ, USA) and incubated for 22 h. Our preliminary experiment validated that 22-h incubation did not affect cell proliferation. The cells invading Matrigel were stained by Giemsa, as described above, and counted.
Interaction between PKIB and PKA-C HA-PKIB and/or PKA-C-Myc expression vectors were cotransfected into COS7 cells, and at 48 h after the transfection, these cells were lysed by lysis buffer (50 mM Tris-HCl (pH7.0), 250 mM sucrose, 1 mM dithiothreitol, 10 mM EDTA, 1 mM EGTA, 5 mM MgCl 2 ). The cell lysate was immunoprecipitated by an anti-HA antibody (Sigma-Aldrich), and these immunoprecipitated products were subjected to western blot analysis with an anti-Myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or an anti-HA antibody. The full-length PKIB cDNA (78 amino acids, NP_115860) was prepared by PCR amplification and inserted into the pGEX-6P-1 vector (GE Healthcare). The recombinant PKIB fused with GST at the N-terminus was expressed in Escherichia coli, BL21 codon plus (Stratagene, La Jolla, CA, USA) and purified with Glutathione Sepharose 4B (GE Healthcare) following the manufacturer's instructions. HA-PKA-C expression vector was transfected into COS-7 cells. After 24-h incubation, cells were lysed with lysis buffer as described above. The cell lysate was incubated with beads that bound to GST-PKIB or GST (a negative control) overnight at 4 1C. These beads were washed with lysis buffer and western blot analysis was performed by using either an anti-GST antibody (Santa Cruz Biotechnology) or an anti-PKA-C antibody (C-20, Santa Cruz Biotechnology).
PKA-C localization
The RNA duplex siPKIB or siEGFP was transfected into PC-3 cells or LNCaP cells using Lipofectamin 2000 (Invitrogen) according to the manufacturer's recommended procedures. After 48-h incubation, cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS for 1 min at room temperature. Non-specific binding was blocked by treatment with PBS containing 3% bovine serum albumin (BSA) for 30 min at room temperature. Cells were incubated for 60 min at room temperature with an anti-PKA-C antibody (Santa Cruz Biotechnology) diluted at 1:200 by PBS containing 3% BSA. After washing with PBS, cells were stained by an fluorescein isothiocyanate-conjugated secondary antibody (Santa Cruz Biotechnology) for 60 min at room temperature, and visualized with Spectral Confocal Scanning Systems. To fractionate the cell lysates, the RNA duplex was transfected into LNCaP cells using Lipofectamin 2000 (Invitrogen) according to the manufacturer's recommended procedures. After 48-h incubation, cells were harvested and these cell lysates were fractionated by NE-PER Nuclear and Cytoplasmic Extraction Reagent (Pierce, Rockford, IL, USA). A total of 30 mg proteins of the fractionated cell lysates were western-blotted by using anti-PKA-C antibody, antilaminB antibody (Calbiochem, San Diego, CA, USA) for the loading and the nuclear fraction, and anti-HSP90 antibody (Santa Cruz Biotechnology) for the cytoplasmic fraction.
